Skip to main content
All lobbying filings

BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Lobbying for BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$280,000
What this organization spent lobbying with its own staff. Reported using IRS section 6033(b)(8) definitions (method B): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Budget/Appropriations

H.R.7148 - Consolidated Appropriations Act, 2026

Health Issues

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

 Bills named in this filing 8

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem